Journal: Frontiers in Cell and Developmental Biology

Article Title: Exosomes Released From Human Bone Marrow–Derived Mesenchymal Stem Cell Attenuate Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Mice

doi: 10.3389/fcell.2021.617589

Figure Lengend Snippet: Human bone marrow–derived mesenchymal stem cell (hBMSC)–derived exosomes inhibited inflammatory response related to acute graft-versus-host disease (aGVHD) in vitro and in vivo . (A) Levels of inflammatory cytokines in culture supernatants produced by PHA/rhIL-2-activated human peripheral blood mononuclear cells with or without hBMSC-derived exosomes. (B) Levels of inflammatory cytokines in serum samples in aGVHD mice that did or did not receive hBMSC-derived exosomes on day 5 and day 10 after transplantation. * p < 0.05, ** p < 0.01. IL-2, interleukin-2; INF-γ, interferon-γ; TNF-α, tumor necrosis factor-α. N = 3–8 in each group. Data were representative of at least two independent experiments.

Article Snippet: Human peripheral blood mononuclear cells (hPBMCs) were purchased from Shanghai Obio Technology (China) and maintained in DMEM (Gibco) containing 10% fetal bovine serum (Gibco) with standard incubation conditions (5% CO 2 and 37°C). hPBMCs were exposed to 5 μg/ml of phytohemagglutinin (PHA) and 5 ng/ml of recombinant human interleukin 2 (rhIL-2), and then incubated with 100 μg/ml Msc-exo or Fib-exo (control).

Techniques: Derivative Assay, In Vitro, In Vivo, Produced, Transplantation Assay